Clinical Trial

Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized Controlled Trial

Study acronym: ESCIHP
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated August 20, 2024 (before its estimated December 2024 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is: 1. To evaluate the efficacy of Songling Xuemaikang Capsules(SLXMKC) with grade 1 hypertension. 2. To reveal the potiential effects of SLXMKC on vascular function and structure of patients with grade 1 hypertension. 3. To explore the underlying mechanisms of the therapeutic effects of SLXMKC on the intervention of grade 1 hypertension.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-10-17; most recent amendment 2024-08-17.
Status change: Not Yet Recruiting → Recruiting 2024-06-17
Trial Details
NCT Number NCT06093932
Lead Sponsor Xiyuan Hospital of China Academy of Chinese Medical Sciences
Collaborators: Suzhou Hosptial of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine
Conditions Hypertension,Essential
Enrollment 100 participants
Start Date 2024-04-07
Primary Completion 2024-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2024-08-20